Alamar Biosciences

Public

Fremont, CaliforniaBiotechhttps://alamarbio.com

Alamar Biosciences is now publicly traded

The data on this page reflects Alamar Biosciences's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Apr 20, 2026

Last Round

Convertible Debt

Jan 11, 2026

Total Funding Raised

$518.22M

Company Overview

Alamar Biosciences is a biotechnology company that develops a precision proteomics platform for protein biomarker detection and analysis to facilitate early disease diagnosis.

Sector

Biotech

Verticals

Life Sciences, LOHAS & Wellness, Oncology

AI Layer

Non-AI

Keywords

proteomicsbiomarker discoveryNULISAprotein detectionlife science toolsproteomic profilingliquid biopsyrazor and bladeneurodegenerative disease researchblood-based biomarkersautomated instrumentationassay kitsclinical researchprecision medicinemulti-omics

Alamar Biosciences Comparables

Compare Alamar Biosciences with similar companies based on industry and business-model similarity.

Alamar Biosciences comparables — related companies by embedding similarity
Company	Similarity	Market Cap
Seer	88%	Book a demo
Quanterix Corporation	88%	Book a demo
Nautilus Biotechnology	87%	Book a demo

Book a demo to see all comparables

For institutional investors. Book with your work email.

Alamar Biosciences Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
IPO	Apr 20, 2026	Book a demo	Book a demo	Book a demo	Book a demo
Convertible Debt	Jan 11, 2026	Book a demo	Book a demo	Book a demo	Book a demo
Grant	Jan 8, 2025	Book a demo	Book a demo	Book a demo	Book a demo
Series C	Feb 26, 2024	Book a demo	Book a demo	Book a demo	Book a demo
Series B	Sep 8, 2021	Book a demo	Book a demo	Book a demo	Book a demo
Series A	Apr 13, 2021	Book a demo	Book a demo	Book a demo	Book a demo

Book a demo to see all 7 rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Steve Chen

Founder, COO

Founding Team

Xiao-Jun Ma

Chief Technology Officer

Executive Team

Tod White

Chief Financial Officer & Chief Business Officer

Executive Team

For institutional investors. Book with your work email.

Alamar Biosciences Investors

Notable investors and investment history

Alamar Biosciences investors
Investor	Rounds
U.S. Department of Health and Human Services	Grant
Braidwell	Convertible Debt
Gates Ventures	Grant
Morningside Ventures	Series B
ARCH Venture Partners	Series C
T. Rowe Price	Convertible Debt
TMCP	Series C

Book a demo to see all investors

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

has_revenue_increased_byNov 4, 2026
Alamar Biosciences, Inc. reports third-quarter revenue growth of 68% year over year in New York on Nov 4th '26.
partners_withNov 3, 2026
Alamar Biosciences, Inc. partners with GlaxoSmithKline plc on a strategic scientific collaboration using the NULISA platform to analyze more than 60,000 serum samples and study protein signatures across respiratory, liver, kidney, neurological and autoimmune conditions in California on Nov. '26.
partners_withNov 3, 2026
On Nov 3rd '26, Alamar Biosciences, Inc. announces a large-scale research collaboration with UK Biobank to profile 80,000 samples; the project is included in updated guidance, with expected revenue undisclosed.
hiresSep 18, 2026
Alamar Biosciences, Inc. appointed Robert Ragusa to its board on Sep 1st '26, where he also joined the Audit, Compensation, and Nominating and Corporate Governance Committees.
attends_eventSep 1, 2026
Alamar Biosciences, Inc. is scheduled to participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Sep 15th '26, with management taking part in a fireside chat at 4:05 p.m. Eastern Time.